MenuМеню
  • Home
  • About Us
  • Medicines
  • Partnering
  • Professionals
  • Responsibility
  • News & Media
  • Careers
  • Investors
  • English
  • Bulgarian

News and Media

  • Financial News
  • News
  • Opinion Pieces
  • Press Releases
  • July 19, 2016

    After consecutive successful international procedure Tchaikapharma received Marketing Authorisation for the medicinal product Tamayra, for which Bulgaria is the country of reference.

    After successfully completing the third for the company Decentralised Procedure (DCP) Tchaikapharma High Quality Medicines Inc. received Marketing Authorisation for the medicinal product Tamayra 5 mg/5 mg hard capsules and Tamayra 10 mg/5 mg hard capsules, for which Bulgaria is the country of reference This is the first international procedure for Marketing Authorisation of medicinal […]

  • July 14, 2016

    The Bulgarian Drug Agency issues a new marketing authorisation for Tchaikapharma’s medicinal product Ibodria

    Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Ibodria 6 mg/6 ml concentrate for solution for infusion and Ibodria 3 mg/3 ml solution for injection in pre-filled syringe. The active substance contained is Ibandronic acid (as ibandronate sodium monohydrate). The medicinal product is indicated for the treatment of osteoporosis in […]

  • June 30, 2016

    Tchaikapharma’s Amariton won the Award for best Bulgarian medicinal product subject to medicinal prescription

    The Bulgarian Pharmaceutical Union awarded Tchaikapharma High Quality Medicines Inc. for cardiological medicinal product Amariton in the category “Medicinal Product Subject to Medicinal Prescription – made in Bulgaria” for 2016. The Awards ceremony took place at the Tenth anniversary edition of the Bulgarian Pharmaceutical Days, held from the 24th to 26th of June 2016 at […]

  • June 27, 2016

    Atorva is the new product of Tchaikapharma with Marketing Authorisation.

    Tchaikapharma High Quality Medicines Inc. was granted Marketing Authorisations for the medicinal products Atorva 40 mg and 80 mg film-coated tablets. Each tablet contains the active substance atorvastatin as atorvastatin calcium. Atorva is indicated: – as an adjunct to diet to reduce elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in adults, adolescents and children […]

  • May 13, 2016

    Successful completion of the Decentralised Procedure for the medicinal product Tamayra

    On 10/05/2016, the BDA successfully completed within the specified period the first decentralised procedure (DCP) for marketing authorisation of medicinal products for which Bulgaria is the Reference Member State (RMS). A team of experts from the BDA assessed the documentation, in connection with the Marketing Authorisation of medicinal products Tamayra 5 mg/5 mg hard capsules […]

  1. Previous
  2. 1
  3. ...
  4. 11
  5. 12
  6. 13
  7. 14
  8. 15
  9. 16
  10. 17
  11. ...
  12. 36
  13. Next
Copyright © 2010-2025 Tchaikapharma Inc.
  • Contact Us